Compare · LLY vs PTPI
LLY vs PTPI
Side-by-side comparison of Eli Lilly and Company (LLY) and Petros Pharmaceuticals Inc. (PTPI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PTPI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.14T, about 33963.8x PTPI ($33.5M).
- Over the past year, LLY is up 76.6% and PTPI is up 0.0% - LLY leads by 76.6 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 1 for PTPI).
- LLY has more recent analyst coverage (25 ratings vs 0 for PTPI).
- Company
- Eli Lilly and Company
- Petros Pharmaceuticals Inc.
- Price
- $1209.09-0.89%
- $0.06-50.66%
- Market cap
- $1.14T
- $33.5M
- 1M return
- +4.54%
- +0.00%
- 1Y return
- +76.61%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 17
- 1
- Recent ratings
- 25
- 0
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Petros Pharmaceuticals Inc.
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.
Latest LLY
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
- SVP, Finance, & CAO Zakrowski Donald A sold $2,370,020 worth of shares (2,000 units at $1,185.01) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 1,526 units (SEC Form 4)
- EVP, GC & Secretary Hakim Anat sold $5,950,000 worth of shares (5,000 units at $1,190.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Eli Lilly and Company
- Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
- EVP, Global Quality Seymour Melissa converted options into 981 shares and covered exercise/tax liability with 439 shares, increasing direct ownership by 103% to 1,067 units (SEC Form 4)
- Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
Latest PTPI
- SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
- New insider Weinstein Robert claimed ownership of 636,004 shares (SEC Form 3)
- Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Walker Wayne Remell was granted 375,000 shares, increasing direct ownership by 74% to 881,333 units (SEC Form 4)
- Officer Boctor Fady was granted 375,000 shares, increasing direct ownership by 72% to 894,986 units (SEC Form 4)
- Director Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 99% to 3,762,334 units (SEC Form 4)
- Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 99% to 8,790,450 units (SEC Form 4)
- Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
- SEC Form 10-K filed by Petros Pharmaceuticals Inc.